Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Eric_Shaff
|
| gptkbp:collaboratesWith |
gptkb:Nestlé_Health_Science
|
| gptkbp:FDAApproved |
gptkb:SER-109
|
| gptkbp:focusesOn |
microbiome therapeutics
|
| gptkbp:foundedYear |
2010
|
| gptkbp:founder |
gptkb:David_Berry
|
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Seres Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:mission |
transform the lives of patients worldwide with revolutionary microbiome therapeutics
|
| gptkbp:notableAchievement |
developed first FDA-approved microbiome therapeutic
|
| gptkbp:numberOfEmployees |
100-200 (approximate)
|
| gptkbp:product |
gptkb:SER-109
gptkb:SER-155 gptkb:SER-287 gptkb:SER-301 |
| gptkbp:publiclyTraded |
yes
|
| gptkbp:specializesIn |
oral microbiome therapeutics
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:MCRB
|
| gptkbp:website |
https://www.serestherapeutics.com/
|
| gptkbp:bfsParent |
gptkb:Flagship_Pioneering
|
| gptkbp:bfsLayer |
6
|